Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer.
Weiwei HuangChao LiMulan ChenDuanyu LinFan WuXinhua ChenNani LiLili WangJian LiuPublished in: OncoTargets and therapy (2020)
A 62-year-old postmenopausal woman was diagnosed with breast cancer in her left breast and received modified radical mastectomy (molecular type: hormone-receptor-positive human epidermal growth factor receptor-2 negative). After that, she received postoperative chemotherapy and radiotherapy. After 2 years of tamoxifen adjuvant endocrine treatment, the patient inccurred recurrence with metastasis. PET-CT scanning showed metastasis in the left thoracic wall, the sixth left rib, and the right lower lobe of the lung. Multiple lymph node metastases were observed throughout the body. Palbociclib in combination with an aromatase inhibitor (AI) was used, but the metastatic lesion at the sixth left rib increased than before. Subsequently, the lesion shrunk and the clinical symptoms were relieved, which was considered as a pseudoprogression. Herein, we reported a pseudoprogression in the breast cancer patient after treatment with palbociclib plus AI.
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- pet ct
- lymph node
- case report
- early stage
- artificial intelligence
- endothelial cells
- tyrosine kinase
- squamous cell carcinoma
- small cell lung cancer
- spinal cord
- radiation therapy
- patients undergoing
- physical activity
- deep learning
- mass spectrometry
- bone mineral density
- body composition
- sentinel lymph node
- postmenopausal women